Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Inclusion Criteria: * Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma. * Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy. * Measurable disease per RECIST 1.1. * At least 18 years of age. * ECOG performance status ≤ 1 * Adequate bone marrow and organ function within 14 days before first dose of study treatment as defined below: * Absolute neutrophil count ≥ 1.5 K/cumm without granulocyte colony-stimulating factor support within 2 weeks of collection * Platelets ≥ 100 K/cumm without transfusion within 2 weeks of collection * Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks of collection * INR ≤ 1.5 x ULN and aPTT ≤ 1.2 x ULN; for subjects on Factor Xa inhibitors, this criterion does not apply. * Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease, ≤ 3.0 x IULN) * AST(SGOT)/ALT(SGPT)/alkaline phosphatase (ALP) ≤ 3.0 x IULN (for subjects with documented bone metastasis, ALP ≤ 5.0 x IULN) * Serum albumin ≥ 2.8 g/dL * Serum creatine ≤ 1.5 x IULN or calculated creatinine clearance ≥ 40 mL/min by Cockcroft-Gault * UPCR ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine * Recovery to baseline or ≤ grade 1 from AEs, including immune-related AEs related to any prior treatments, unless AEs are clinically nonsignificant and/or stable on supportive therapy (e.g., physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alope…